Protagonist Therapeutics Announces FDA Approval of MIMRYLO for Polycythemia Vera
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Protagonist Therapeutics has received U.S. FDA approval for its hepcidin mimetic peptide MIMRYLO (rusfertide) to treat polycythemia vera. This new treatment, developed in collaboration with Takeda, represents a significant advancement for patients with this rare blood cancer.
The approval marks a milestone for both companies, as MIMRYLO offers a novel therapeutic option for managing polycythemia vera, a condition characterized by an overproduction of red blood cells. The collaboration aims to improve patient outcomes and expand treatment options in the oncology space.
Protagonist TherapeuticsTakedaMIMRYLO
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera”
SEC Filing — Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera“Mimrylo, from Takeda and Protagonist, is a new kind of treatment for the blood cancer polycythemia vera.”
stat news — STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer